Balancing the innate immune system in tumor development
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Cells of the innate immune system have a dual role in cancer development in both tumor initiation and progression. Innate immune cells can, on the one hand, aid malignant transformation and tumor outgrowth and, on the other hand, prevent tumor progression. The innate immune system has the ability to tune the inflammatory response and is a key player in cancer-related inflammation, which can precede development of malignancy or be induced by oncogenic changes promoting a pro-tumor inflammatory milieu. In this review we discuss the emerging cellular and molecular mechanisms of the innate immune system and inflammation in tumor initiation and progression and point to the outstanding questions that remain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472 · cited 1×
“While originally thought to be a homogeneous population of pro-inflammatory cells, neutrophils are now known to be essential during both pro- and anti-inflammatory responses and emerging identification of neutrophil subsets suggest these cells are more heterogeneous [99].”
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 1×
“Importantly, the macrophages in the Stat3 knockout mice overproduced proinflammatory cytokines, including TNF-α and IL-6, which, like interferon-γ (IFN-γ), have an important role in promoting tumor initiation and progression (reviewed in [19, 20]).”
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 7×
“Pro-inflammatory mediators (IL-6, IFN-γ, TNF-α, ROS and RNI) activate STAT3 and NF-κB and induce genetic instability.”
BackgroundInfluentialTumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 2×
“Yet another way by which DCs lose their anti-tumor function is due to hypoxia[13].”
BackgroundCCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“Yet another population of TAMs, the monocytes displaying the C-C chemokine receptor type 2 (CCR2), are preferentially recruited to the metastatic site by CCL2, which can be derived from either tumor or stromal cells[58, 59].”
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 1×
“Moreover, treatment with a CSF-1R inhibitor in a glioblastoma mouse model re-educates M2 macrophages, which, importantly, promotes regression of established high-grade glioma[48].”
BackgroundInflammation-induced cancer: Crosstalk between tumours, immune cells and microorganisms
Elinav, E., Nowarski, R., Thaiss, C. A., Hu, B., Jin, C., & Flavell, R. A. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3611 · Cited by 2,000
Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · cited 2×
“Obesity further induces elevated production of both IL-6 and TNF-α, which activates STAT3 in hepatocytes promoting hepatic inflammation that eventually causes HCC development[11].”
De Palma, M., Venneri, M. A., Galli, R., Sergi, L. S., Politi, L. S., Sampaolesi, M., & Naldini, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.08.002 · Cited by 1,311
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S.-R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101159 · Cited by 1,192
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
T-helper-1-cell cytokines drive cancer into senescence
Braumüller, H., Wieder, T., Brenner, E., Aßmann, S., Hahn, M., Alkhaled, M., Schilbach, K., Essmann, F., Kneilling, M., Griessinger, C., et al. (2013) · Nature · doi:10.1038/nature11824 · Cited by 720
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122308 · Cited by 529
Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., Yagita, H., Takaoka, A., & Tahara, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106645108 · Cited by 479
Katoh, H., Wang, D., Daikoku, T., Sun, H., Dey, S. K., & DuBois, R. N. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.009 · Cited by 477 · cited 1×
“CXCR2+ MDSCs are recruited to inflamed colon where they promote chronic inflammation and contribute to tumor initiation and development of colitis-associated cancer [93].”
BackgroundIannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
Cancer immunoediting by the innate immune system in the absence of adaptive immunity
O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112738 · Cited by 348 · cited 1×
“NK cells reprogram macrophages into becoming tumoricidal through the production of IFN-γ, and the overexpression of miR-155 in TAMs repolarizes them into a tumoricidal M1 phenotype[45, 46].”
Yang, J., Liao, D., Chen, C., Liu, Y., Chuang, T.-H., Xiang, R., Markowitz, D., Reisfeld, R. A., & Luo, Y. (2013) · Stem Cells · doi:10.1002/stem.1281 · Cited by 301 · cited 1×
“Macrophages can, for example, produce IL-6, epidermal growth factor (EGF) and milk-fat globule epidermal factor VIII, which enhance the tumorigenic capacity of lung, colon, breast and pancreatic cancer cells[26-30].”
Jung, H., Hsiung, B., Pestal, K., Procyk, E., & Raulet, D. H. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120565 · Cited by 123 · cited 1×
“Intriguingly the NKG2D ligand, RAE-1, is upregulated upon activation of RAS and PI3K pathways and by transcription factor E2F in response to proliferation-related signals, pointing to an intricate connection between cell proliferation and the ability of the innate immune system to recognize proliferating cells[41-44].”
Tokuyama, M., Lorin, C., Delebecque, F., Jung, H., Raulet, D. H., & Coscoy, L. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002265 · Cited by 51
Cited by
Gaudino, S. J., & Kumar, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00360 · Cited by 298
Witek Janusek, L., Tell, D., & Mathews, H. L. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.04.012 · Cited by 143
Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development
Kantono, M., & Guo, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01132 · Cited by 133
Liu, T. W., Gammon, S. T., Yang, P., Fuentes, D., & Piwnica-Worms, D. (2021) · Science Signaling · doi:10.1126/scisignal.aax5971 · Cited by 27
Spatiotemporal analysis of tumour-infiltrating immune cells in biliary carcinogenesis
Charbel, A., Tavernar, L., Albrecht, T., Brinkmann, F., Verheij, J., Roos, E., Vogel, M. N., Köhler, B., Springfeld, C., Brobeil, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01933-0 · Cited by 11
Metadata
- Authors
- Hagerling, C., Casbon, A.-J., & Werb, Z.
- Venue
- Trends in Cell Biology
- Publisher
- Elsevier BV
- Published
- 2015-04
- Volume
- 25
- Issue
- 4
- Pages
- 214-220
- ISSN
- 0962-8924 (ISSN-L)
- OpenAlex
- W1965765543
- Cited by
- 133
- References
- 25
- FWCI
- 0.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.